Gain Therapeutics, Inc SEC filings GANX
Gain Therapeutics, Inc has 240 filings in SEC EDGAR's recent list, going back to Jul 30, 2020. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 28, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 28, 2026 | Oct 22, 2026 |
| 8-K |
Current report
Other events
|
Oct 1, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 28, 2026 | Sep 22, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Other events
|
Jul 16, 2026 | Jul 16, 2026 |
| 8-K |
Current report
Other events
|
Jun 29, 2026 | Jun 29, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 25, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Other events
|
May 26, 2026 | May 26, 2026 |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 11, 2026 | May 11, 2026 |
| ARS | Annual report to shareholders | Apr 28, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEF 14A | Proxy statement | Apr 28, 2026 | Jun 24, 2026 |
| 10-K | Annual report | Mar 26, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 26, 2026 | Mar 26, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 18, 2026 | Mar 18, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 3, 2026 | Feb 3, 2026 |
| 8-K |
Current report
Other events
|
Dec 18, 2025 | Dec 18, 2025 |
| S-8 | Employee stock plan registration | Dec 3, 2025 | — |
| 8-K |
Current report
Other events
|
Nov 28, 2025 | Nov 28, 2025 |
| 424B5 | Prospectus supplement | Nov 28, 2025 | — |
| 10-Q | Quarterly report | Nov 12, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2025 | Nov 12, 2025 |
| S-3/A | Filing | Nov 7, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 14, 2025 | Oct 14, 2025 |
| 8-K |
Current report
Officer or director change
|
Oct 9, 2025 | Oct 6, 2025 |
| 8-K |
Current report
Other events
|
Oct 6, 2025 | Oct 6, 2025 |
| 10-Q | Quarterly report | Aug 12, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2025 | Aug 12, 2025 |
| 424B5 | Prospectus supplement | Jul 17, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Jul 17, 2025 | Jul 15, 2025 |
| 424B5 | Prospectus supplement | Jul 15, 2025 | — |
| 8-K |
Current report
Other events
|
Jun 30, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 24, 2025 | Jun 24, 2025 |
| UPLOAD | Letter from the SEC | Jun 4, 2025 | — |
| S-3 | Shelf registration | May 28, 2025 | — |
| 10-Q | Quarterly report | May 14, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 14, 2025 | May 14, 2025 |
| ARS | Annual report to shareholders | Apr 29, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 29, 2025 | — |
| DEF 14A | Proxy statement | Apr 29, 2025 | Jun 24, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2025 | Jun 24, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 10, 2025 | Apr 10, 2025 |
| 10-K | Annual report | Mar 27, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 27, 2025 | Mar 27, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 6, 2025 | Feb 6, 2025 |
| 8-K |
Current report
Listing notice
|
Jan 15, 2025 | Jan 8, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jan 7, 2025 | Jan 6, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 23, 2024 | Dec 23, 2024 |
| 10-Q | Quarterly report | Nov 14, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 14, 2024 | Nov 14, 2024 |
| 8-K |
Current report
Other events
|
Oct 21, 2024 | Oct 21, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 8, 2024 | Oct 7, 2024 |
| S-8 | Employee stock plan registration | Sep 19, 2024 | — |
| 424B5 | Prospectus supplement | Sep 6, 2024 | — |
| 8-K |
Current report
Material agreement
|
Sep 6, 2024 | Sep 6, 2024 |
| 10-Q | Quarterly report | Aug 8, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2024 | Aug 8, 2024 |
| 8-K |
Current report
Listing notice
|
Jul 12, 2024 | Jul 11, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jul 9, 2024 | Jul 9, 2024 |
| FWP | Free writing prospectus | Jul 1, 2024 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 28, 2024 | Jun 25, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 25, 2024 | Jun 24, 2024 |
| 424B5 | Prospectus supplement | Jun 17, 2024 | — |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jun 14, 2024 | Jun 13, 2024 |
| 424B5 | Prospectus supplement | Jun 13, 2024 | — |
| 10-Q | Quarterly report | May 14, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 14, 2024 | May 14, 2024 |
| ARS | Annual report to shareholders | Apr 26, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 24, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Apr 8, 2024 | Apr 5, 2024 |
| 10-K | Annual report | Mar 26, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 26, 2024 | Mar 26, 2024 |
| 8-K |
Current report
Officer or director change
|
Feb 22, 2024 | Feb 19, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 31, 2024 | Jan 31, 2024 |
| 424B3 | Prospectus | Jan 2, 2024 | — |
| EFFECT | Filing | Dec 29, 2023 | — |
| CORRESP | Letter to the SEC | Dec 22, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 21, 2023 | — |
| S-1 | Registration statement | Dec 19, 2023 | — |
| 424B5 | Prospectus supplement | Nov 24, 2023 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Nov 22, 2023 | Nov 20, 2023 |
| 424B5 | Prospectus supplement | Nov 20, 2023 | — |
| 8-K |
Current report
Agreement ended
|
Nov 17, 2023 | Nov 17, 2023 |
| 10-Q | Quarterly report | Nov 14, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 14, 2023 | Nov 14, 2023 |
| 10-Q | Quarterly report | Aug 10, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2023 | Aug 10, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 26, 2023 | Jun 23, 2023 |
| S-8 | Employee stock plan registration | May 30, 2023 | — |
| 10-Q | Quarterly report | May 12, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Results of operations
|
May 12, 2023 | May 12, 2023 |
| ARS | Annual report to shareholders | Apr 28, 2023 | Dec 31, 2022 |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 23, 2023 |
| 8-K |
Current report
Officer or director change
|
Apr 28, 2023 | Apr 27, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Apr 12, 2023 | Apr 6, 2023 |
| 10-K | Annual report | Mar 23, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 23, 2023 | Mar 23, 2023 |
| 8-K |
Current report
Officer or director change
|
Dec 16, 2022 | Dec 12, 2022 |
| 10-Q | Quarterly report | Nov 10, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2022 | Nov 10, 2022 |
| 8-K |
Current report
Officer or director change, Other events
|
Sep 20, 2022 | Sep 19, 2022 |
| 10-Q | Quarterly report | Aug 8, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2022 | Aug 8, 2022 |
| S-8 | Employee stock plan registration | Jul 15, 2022 | — |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2022 | Jun 16, 2022 |
| EFFECT | Filing | Jun 1, 2022 | — |
| CORRESP | Letter to the SEC | May 31, 2022 | — |
| S-3/A | Filing | May 23, 2022 | — |
| UPLOAD | Letter from the SEC | May 20, 2022 | — |
| S-3 | Shelf registration | May 18, 2022 | — |
| 10-Q | Quarterly report | May 16, 2022 | Mar 31, 2022 |
| 8-K |
Current report
Results of operations
|
May 16, 2022 | May 16, 2022 |
| DEF 14A | Proxy statement | May 13, 2022 | Jun 16, 2022 |
| 10-K/A | Amended annual report | May 2, 2022 | Dec 31, 2021 |
| 10-K | Annual report | Mar 25, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Results of operations
|
Mar 24, 2022 | Mar 24, 2022 |
| 8-K |
Current report
Officer or director change
|
Dec 28, 2021 | Dec 23, 2021 |
| 10-Q | Quarterly report | Nov 12, 2021 | Sep 30, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2021 | Nov 12, 2021 |
| 8-K |
Current report
Officer or director change, Other events
|
Oct 20, 2021 | Oct 15, 2021 |
| 10-Q | Quarterly report | Aug 12, 2021 | Jun 30, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2021 | Aug 11, 2021 |
| 10-Q | Quarterly report | May 10, 2021 | Mar 31, 2021 |
| 8-K |
Current report
Results of operations
|
May 10, 2021 | May 10, 2021 |
| 8-K |
Current report
Other events
|
May 4, 2021 | May 3, 2021 |
| S-8 | Employee stock plan registration | Apr 6, 2021 | — |
| 8-K |
Current report
Material agreement, Change to shareholder rights, Bylaw or fiscal year change
|
Mar 22, 2021 | Mar 17, 2021 |
| 424B4 | Prospectus | Mar 22, 2021 | — |
| EFFECT | Filing | Mar 17, 2021 | — |
| CERT | Filing | Mar 17, 2021 | — |
| 8-A12B | Form 8-a12b | Mar 17, 2021 | — |
| CORRESP | Letter to the SEC | Mar 16, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 16, 2021 | — |
| CORRESP | Letter to the SEC | Mar 15, 2021 | — |
| CORRESP | Letter to the SEC | Mar 15, 2021 | — |
| CORRESP | Letter to the SEC | Mar 15, 2021 | — |
| S-1/A | Amended registration statement | Mar 15, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 12, 2021 | — |
| CORRESP | Letter to the SEC | Mar 10, 2021 | — |
| S-1/A | Amended registration statement | Mar 10, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 23, 2021 | — |
| CORRESP | Letter to the SEC | Feb 19, 2021 | — |
| S-1 | Registration statement | Feb 19, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 3, 2021 | — |
| DRSLTR | Filing | Jan 29, 2021 | — |
| DRS/A | Filing | Jan 29, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 19, 2021 | — |
| DRSLTR | Filing | Jan 8, 2021 | — |
| DRS/A | Filing | Jan 8, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 14, 2020 | — |
| DRSLTR | Filing | Nov 16, 2020 | — |
| DRS | Filing | Nov 16, 2020 | — |
| D | Filing | Jul 30, 2020 | — |
Showing 157 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GANX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bethesda, MD
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1819411
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.